Industry approaches to realise the benefits of personalised medicine during drug development

08.09.2010

Industry approaches to realise the benefits of personalised medicine during drug development

On 8 September 2010, EuropaBio organised its second workshop on personalised medicine entitled: Industry approaches to realise the benefits of personalised medicine during drug development. The traditional approach to diagnosis and treatment has been based around phenotypic definitions of disease; grouping patients into broad groups with similar symptoms. Pharmaceutical and biotechnology companies have developed medicines for these broad populations, and the regulatory assessment of risk and benefit has been based the average clinical response across these groups. Medicines which can be used in a wide range of patients offer, and will continue to offer, considerable clinical and economic utility in healthcare. This model of medicine has led to many advances, but regulators, companies and clinicians have always known that not all patients will respond in the same way to the same therapy.

Developments in personalised medicine offer the opportunity to use latest advances in biological knowledge and technology, such as the completion of the human genome mapping, to improve understanding of inter-individual variability, and to further focus both innovation in medicinal development and healthcare delivery around patients. The second EuropaBio workshop on personalised medicine looked at the impact of personalised medicine on drug discovery and development as well as to better understand the specific challenges (e.g. policy and regulatory) and opportunities (e.g. collaboration and partnership) in the area, and interact with experts who deal with personalised medicine in drug development on a day-to-day basis.

Four presentations gave an overview of the opportunities and challenges of personalised medicine in drugs and diagnostics development:

The workshop backgrounder can be downloaded here

 

 

Latest Position papers